The factor VIII assay problem: Neither rhyme nor reason

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 11, 2003, Pages 2275-2279

  Lollar, P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CHROMOGENIC SUBSTRATE; DIAGNOSTIC AGENT;

DOSE RESPONSE; HUMAN; NOTE; STANDARD;

CHROMOGENIC COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HUMANS;

EID: 2542628723     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00484.x     Document Type: Note

References (18)

1. Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM, and ReFacto-AICE Study Group. A. multicentre pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003; 1: 2283-9.
2. Mikaelsson M, Oswaldsson U. Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. Semin Thromb Hemost 2002; 28: 257-64.
3. Lee CA, Owens D, Bray G, Giangrande P, Collins P, Hay C, Gomperts E, Schroth P, Barrowcliffe T. Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay. Thromb Haemost 1999; 82: 1644-7.
4. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests. J Lab Clin Med 1953; 41: 637-47.
5. Biggs R, Eveling J, Richards G. The assay of antihaemophilic globulin. Br J Haematol 1955; 1: 20-34.
6. Finney DJ. Statistical Method in Biologic Assay. New York: Macmillan, 1978.
7. Raut S, Heath AB, Barrowcliffe TW. A collaborative study to establish the 6th International Standard for factor VIII concentrate. Thromb Haemost 2001; 85: 1071-8.
8. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardi zation, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
9. Hubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001; 113: 533-6.
10. Lusher JM, Hillman-Wiseman C, Hurst D. In vivo recovery with products of very high purity-assay discrepancies. Haemophilia 1998; 4: 641-5.
11. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13-23.
12. Mikaelsson M. Factor VIII assays. Int Monitor Hemophilia 2000; 8: 4-8.
13. Hubbard AR, Rigsby P, Barrowcliffe TW. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586). Thromb Haemost 2001; 85: 634-8.
14. Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 646-50.
15. Mikaelsson M, Oswaldsson U, Frank L. Comparison of activity and antigen measurements in a pharmacokinetic study of recombinant factor VIIII SQ. Haemophilia 1998; 45: 187a.
16. Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000; 84: 942-8.
17. Parker ET, Lollar P. A quantitative measure of the efficacy of factor VIII in hemophilia A mice. Thromb Haemost 2003; 89: 480-5.
18. Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 634-40.